The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

Inclusion Criteria: * Female and male age range of 40-75 * Patients who are in the induction phase of warfarin * Patients receiving warfarin to prevent or treat thromboembolic conditions (e.g., post orthopedic surgery prophylaxis, deep venous thrombosis, atrial fibrillation, pulmonary embolism, heart failure) * Patient willing to provide informed consent prior to the specimen collection procedure * Patient whose physician is willing to order the genetic test Exclusion Criteria: * Age \< 40 or \> 75 * Previous use of warfarin within 180 days of initiating new warfarin therapy * Hospitalized for seven or more days before first claim for warfarin * Previous history of genetic testing for warfarin therapy * Known hypersensitivity to warfarin * Patient or physician refusal to participate in the study * Patients using warfarin residing in Olmsted County, MN